HHLA2 (A-20): sc-99927



The Power to Question

BACKGROUND

Human endogenous retroviruses (HERVs) are repetitive elements that are derived from ancient germline retroviral infections. Due to their ability to move and insert next to certain genes and alter expression patterns, HERVs have been linked to several chronic diseases such as nervous systemic diseases, cancer, autoimmune and connective tissue diseases. The HERV-H family is the most abundant HERV family and has been implicated in the expression of a variety of adjacent genes. Proteins belonging to the HERV-H family are divided into one major and two minor groups based on sequence divergence. As a member of the HERV-H family, HHLA2 (HERV-H LTR-associating protein 2) is a 414 amino acid single-pass type I membrane protein that contains one Ig-like C1-type (immunoglobulin-like) domain and two Ig-like V-type (immunoglobulin-like) domains. HHLA2 is primarily expressed in kidney, lung and intestinal tissues.

REFERENCES

- Feuchter-Murthy, A.E., et al. 1993. Splicing of a human endogenous retrovirus to a novel phospholipase A2 related gene. Nucleic Acids Res. 21: 135-143.
- Urnovitz, H.B., et al. 1996. Human endogenous retroviruses: nature, occurrence, and clinical implications in human disease. Clin. Microbiol. Rev. 9: 772-99
- 3. Kowalski, P.E., et al. 1999. Intergenic splicing between a HERV-H endogenous retrovirus and two adjacent human genes. Genomics 57: 371-379.
- Mager, D.L., et al. 1999. Endogenous retroviruses provide the primary polyadenylation signal for two new human genes (HHLA2 and HHLA3). Genomics 59: 255-263.
- Online Mendelian Inheritance in Man, OMIM™. 1999. Johns Hopkins University, Baltimore, MD. MIM Number: 604371. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/
- 6. Jern, P., et al. 2002. Full-length HERV-H elements with env SU open reading frames in the human genome. AIDS Res. Hum. Retroviruses 18: 671-676.
- 7. Yi, J.M., et al. 2004. Evolutionary implication of human endogenous retrovirus HERV-H family. J. Hum. Genet. 49: 215-219.
- Yi, J.M., et al. 2006. Human endogenous retrovirus HERV-H family in human tissues and cancer cells: expression, identification, and phylogeny. Cancer Lett. 231: 228-239.
- Balada, E., et al. 2009. Molecular mechanisms mediated by human endogenous retroviruses (HERVs) in autoimmunity. Rev. Med. Virol. 19: 273-286.

CHROMOSOMAL LOCATION

Genetic locus: HHLA2 (human) mapping to 3q13.13.

SOURCE

HHLA2 (A-20) is an affinity purified goat polyclonal antibody raised against a peptide mapping near the C-terminus of HHLA2 of human origin.

PRODUCT

Each vial contains 200 μg IgG in 1.0 ml of PBS with <0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-99927 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

HHLA2 (A-20) is recommended for detection of HHLA2 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with HHLA3.

Suitable for use as control antibody for HHLA2 siRNA (h): sc-78498, HHLA2 shRNA Plasmid (h): sc-78498-SH and HHLA2 shRNA (h) Lentiviral Particles: sc-78498-V.

Molecular Weight of HHLA2: 47 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 Fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com